HighTower Advisors
ABCL icon

HighTower Advisors’s AbCellera Biologics ABCL Stock Holding History

HighTower Advisors’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$847K Buy
107,933
+12,000
+13% +$58.7K ﹤0.01% 2351
2026
Q1 		$335K Buy
95,933
+15,970
+20% +$57.5K ﹤0.01% 3067
2025
Q4 		$273K Buy
79,963
+49,750
+165% +$222K ﹤0.01% 3119
2025
Q3 		$152K Buy
30,213
+16,092
+114% +$70.9K ﹤0.01% 3449
2025
Q2 		$48.4K Sell
14,121
-7,365
-34% -$18.3K ﹤0.01% 3550
2025
Q1 		$47.9K Sell
21,486
-49,600
-70% -$142K ﹤0.01% 3459
2024
Q4 		$208K Buy
71,086
+60,600
+578% +$169K ﹤0.01% 3165
2024
Q3 		$27K Sell
10,486
-3,500
-25% -$9.7K ﹤0.01% 3483
2024
Q2 		$42K Sell
13,986
-30,088
-68% -$114K ﹤0.01% 3328
2024
Q1 		$200K Buy
44,074
+3,103
+8% +$15.8K ﹤0.01% 2985
2023
Q4 		$235K Buy
40,971
+6,928
+20% +$32.1K ﹤0.01% 2903
2023
Q3 		$158K Buy
+34,043
New +$207K ﹤0.01% 2994

Other funds holding ABCL

TWC
TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CMF
Counterpoint Mutual Funds San Diego, California $1.01B AUM 37.65% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
Guardian Partners Toronto, Canada $1.11B AUM 38.73% 1-Year Est. Return
SOMRS
State of Michigan Retirement System Lansing, Michigan $22.6B AUM 40.24% 1-Year Est. Return
DRP
Decker Retirement Planning Levi, Utah $294M AUM 97.44% 1-Year Est. Return
Daiwa Securities Group
Daiwa Securities Group Tokyo, Japan $51.1B AUM 35.55% 1-Year Est. Return
CFG
Citizens Financial Group Providence, Rhode Island $8.3B AUM 27.66% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

HighTower Advisors's ABCL Position: Q2 2026 in Review

HighTower Advisors increased its AbCellera Biologics (ABCL) stake by 13% in Q2 2026, buying an estimated $58.7K and bringing the position to 107,933 shares worth $847K. The position accounts for ﹤0.01% of the portfolio, ranked #2351.

HighTower Advisors first reported a position in ABCL in Q3 2023 and has held it in 12 quarters since. 62 funds tracked by Wall St. Rank hold ABCL as of Q2 2026.

  • HighTower Advisors held 107,933 shares of AbCellera Biologics worth $847K as of Q2 2026.
  • HighTower Advisors bought 12,000 AbCellera Biologics shares in Q2 2026, an estimated $58.7K.
  • AbCellera Biologics made up ﹤0.01% of HighTower Advisors's portfolio in Q2 2026, its #2351 holding.
  • HighTower Advisors first reported a position in AbCellera Biologics in Q3 2023 and has held it in 12 quarters since.
  • 62 funds tracked by Wall St. Rank held AbCellera Biologics as of Q2 2026.

Based on HighTower Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.